Advertisement

Picture EBD Group BIO-Europe 2020 Digital Event BEU2020 650x81
Document › Details

Boehringer Ingelheim. (2/28/13). "Press Release: Rare Disease Day – Boehringer Ingelheim Announces Initiation of Pivotal Trial Investigating Volasertib in Patients with Acute Myeloid Leukemia [For non-US media only]". Ingelheim.

Organisation Organisation Boehringer Ingelheim (Group)
Products Product volasertib
  Product 2 nintedanib
Person Person Dugi, Klaus (Boehringer 201106 Corporate SVP Medicine)
     


   
Record changed: 2017-04-02

Advertisement

Picture EBD Group BIO-Europe 2020 Digital Event BEU2020 650x81

More documents for Boehringer Ingelheim (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group BIO-Europe 2020 Digital Event BEU2020 650x81




» top